MedTrace Logo

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

NCT04061772 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2019-08-20

No results posted yet for this study

Summary

To evaluate the efficacy and safety of bortezomib combined with CHEP regimen in peripheral T cell lymphoma

Conditions

  • Peripheral T Cell Lymphoma

Interventions

DRUG

Bortezomib

Bortezomib injection

DRUG

Etoposide

Etoposide injection

DRUG

Cyclophosphamide

Cyclophosphamide injection

DRUG

Pharmorubicin

Pharmorubicin injection

DRUG

Prednisone

Prednisone tablet

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Ming Chen, PhD · Zhejiang Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-12
Primary Completion
2021-07-05
Completion
2021-12-05

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04061772 on ClinicalTrials.gov